Together for Better Liver Health: WHA78 Side Event Unites Global Stakeholders to Strengthen Public Health Responses to Metabolic Disease
By GlobeNewswire Published on May 23, 2025, 12:39 IST
Geneva, Switzerland, May 23, 2025 (GLOBE NEWSWIRE) — Global health leaders call for urgent, integrated action on the rising rates of metabolic liver disease during a high-level policy event held on the sidelines of the 78th World Health Assembly and co-hosted by Global Liver Institute (GLI), the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD). This event brought together leading experts, policymakers, public health officials, and advocates to push for stronger public health strategies that address liver disease as part of the global noncommunicable diseases (NCDs) response and highlight the need to embed liver health within national NCD strategies.
'With liver disease now being the fourth leading cause of adult death in Mexico, we are acting early—starting from pregnancy to school-age—with education, screening, and healthier environments. Our vision is prevention-driven and science-led', shared Marta Zapata-Tarres, MD, PhD, Sub Secretary for Health and Director for National Institutes of Health, Mexico.
During the event, GLI released the second edition of the Best Practices in Liver Health Policy report , featuring 5 new case studies from Brazil, Japan, Mexico, Spain, and Qatar to demonstrate the integration of liver health into clinical pathways and broader health frameworks. Mohamed Hassany, MD, Prof., Minister's Assistant for Projects and Public Health Initiatives, Ministry of Health and Population, The Arab Republic of Egypt mentioned, 'The Hepatitis C campaign taught us a vital lesson: data-driven national efforts combined with trained human resources and specialized centers can change the course of a public health crisis. We now have the opportunity to apply these same tools to address severe liver disease.' Speakers championed a comprehensive, cross-sectoral approach to liver health, including early diagnosis and treatment, community-based care models, and policy frameworks aligned with Universal Health Coverage and the WHO Global NCDs Action Plan.
'To overcome barriers like fragmented data and limited access, we are building a smarter, more connected system. By integrating data and partnering with the private sector, we are creating a future where liver health is no longer neglected,' shares Mary Ann Palermo-Maestrai, Undersecretary, Department of Health, Philippines.
As momentum builds toward the 4th United Nations High-Level Meeting (UNHLM) on NCDs in September 2025, GLI will continue to drive global policy action and strengthen international collaboration to secure liver health as a core global health priority.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Cannabis Research Reveals Optimal Water Activity Levels for Enhanced Pre-Roll Quality and Profitability
First-Of-Its-Kind, Peer-Reviewed Study Combines Laboratory Analysis With Consumer Testing To Optimize Cannabis Smoking Experience RENTON, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Custom Cones USA, in partnership with DaySavers, the Cannabis Research Coalition, and The Network of Applied Pharmacognosy (NAP), shares key findings from Phase I Science of Smokability study, a multi-year research project that is transforming understanding of cannabis cultivation, processing, and consumption. The revolutionary study, led by Dr. Allison Justice, Dr. Miyabe Shields, Dr. Riley Kirk, and Dr. Markus Roggen, represents the first peer-reviewed scientific assessment to examine how various cultivation and production techniques affect cannabis products from the consumer perspective, combining laboratory smoking machine analysis with comprehensive consumer surveys. Key Findings Reveal 0.65 aW as Optimal Water Activity Level Phase I research focused on water activity and moisture content effects on cannabis pre-rolls, with results demonstrating that products maintained at 0.65 aW (water activity) consistently delivered superior performance across multiple metrics: Cannabinoid Delivery: Pre-rolls at 0.65 aW produced the highest cannabinoid concentration in smoke, with 0.85 aW samples delivering only 30% of the cannabinoid content compared to optimal levels Terpene Content: The 0.65 aW samples yielded the highest terpene content, delivering more pronounced flavor profiles Consumer Experience: Survey participants reported that 0.65 aW pre-rolls provided a less irritating smoking experience, while 0.45 aW samples produced harsher, more irritating experiences Significant Financial Implications for Cannabis Producers The study reveals substantial economic benefits for producers maintaining proper water activity levels. The research indicates that the difference between 0.45 aW and 0.65 aW water activity levels corresponds to approximately 18.14 grams per pound of flower—representing potential revenue gains of $27.20 per pound at an assumed market price of $1.50 per gram. "This represents about 4% of revenue per pound of flower," explained Harrison Bard, CEO of Custom Cones USA. "For cannabis producers, optimizing water activity levels can simultaneously improve product quality while enhancing profitability." Innovative Research Methodology Sets New Industry Standard Unlike previous cannabis studies, the Science of Smokability employs a unique dual-methodology approach: Laboratory Analysis: Utilizing sophisticated smoking machines and Combustion Smoke Analyzer SCS technology to measure precise cannabinoid and terpene concentrations in smoke Consumer Testing: Comprehensive surveys from paid participants who received pre-rolls in specialized airtight containers to maintain specific water activity levels The study examined high-quality hemp pre-rolls from The Hemp Mine's "FunDip" strain, stabilized at three different water activity levels using digital hygrometers, 0.45 aW, 0.65 aW, and 0.85 aW. Pre-rolls were manufactured on professional pre-roll machines to ensure consistency. 'The Cambustion machine allowed us to test the composition of the smoke instead of the raw material (flower),' said Dr. Shields. 'Every time we light up, there's a chemical reaction, and the smoking machine allows us to look at what molecules are reaching our lungs after they've been smoked.' When combined with consumer feedback, the results provide a comprehensive view of how different production and cultivation variables impact the final consumer version of products. Industry Impact and Implications The research underscores the critical importance of proper curing and moisture management in cannabis production. As the study authors note: "By optimizing water activity levels, it may be possible to enhance the delivery of desirable compounds, such as cannabinoids and terpenes while minimizing the presence of potentially harmful elements." The findings have immediate practical applications for cannabis producers using automated pre-roll filling machines, which typically benefit from lower moisture content around 9%, corresponding to approximately 0.65 aW. 'Our results emphasize that staying as close as possible to the 0.65 threshold allows a higher quality smoking experience,' said Dr. Kirk. About the Science of Smokability Study The Science of Smokability is a multi-year research initiative spearheaded by Custom Cones USA and DaySavers, in partnership with leading cannabis research organizations, the Cannabis Research Coalition and The Network of Applied Pharmacognosy (NAP). The study aims to provide evidence-based insights into cannabis cultivation, processing, and consumption through rigorous scientific methodology. Phase I of the Science of Smokability focused on the effects of water activity and moisture content on the smoking process. Phase II will look at the impact of nutrients on the smokeability and chemistry of smoking. About Custom Cones USA Founded in 2017 by Harrison Bard and Fredrik Rading, Custom Cones USA is a leading pre-roll resource in the cannabis industry. The team has a wealth of knowledge about all aspects of pre-roll manufacturing and the entire pre-roll sector of the cannabis space. From custom-branded pre-rolled cones and wholesale bulk cones, to completely customized pre-roll packaging projects and pre-roll machines, they offer expertise and solutions to companies big and small in all sectors of the pre-roll space. Custom Cones USA wants to help their customers operate with relative ease and ensure both the companies and their customers to have the highest quality smoking experience. Media Contact: Clarissa Colondo customcones@ Editor's Note: Content, brand logos, and additional data visualizations are available for media or brand use with attribution. Interview opportunities with Custom Cones USA analysts are available upon in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Nanotechnology in Cancer Treatment Market Positioned for Transformational Growth by 2029
'Explore how nanomedicine and targeted therapies are shaping the future of cancer care in BCC Research's global market analysis of nanotechnology in oncology.' Boston, June 05, 2025 (GLOBE NEWSWIRE) -- As cancer prevalence continues to rise globally, nanotechnology in cancer treatment is emerging as a transformative force in oncology. Leveraging nanoscale drug delivery systems and precision-targeting techniques, companies such as AstraZeneca, F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb are developing next-generation solutions to enhance therapeutic effectiveness while minimizing harm to healthy cells. According to the report, growing cancer prevalence, rising government funding, and increased pharmaceutical R&D spending are reshaping innovation strategies across the oncology landscape. The global market is projected to grow at a CAGR of 17.4% from 2024 to 2029. As North America continues to lead market expansion and new nanomedicine applications evolve globally, stakeholders must navigate regulatory complexity, manufacturing scalability, and long-term safety considerations to harness the full potential of this technology. Market Overview: Key Insights and Forecast BCC Research's latest report, Nanotechnology in Cancer Treatment: Technologies and Global Markets, delivers a detailed evaluation of the evolving oncology landscape through the lens of nanomedicine. It explores how advances in nanostructured materials, targeted delivery systems, and diagnostic innovations are shaping the future of cancer treatment across major regions. The global market was valued at $102.4 billion in 2023 and is projected to reach $265.4 billion by the end of 2029. The report delivers forward-looking insights based on current market trends and expected developments over the forecast period. It provides a strategic analysis of major segments by product type and cancer type, along with comprehensive coverage of revenue trends, regulatory frameworks, ESG priorities, technological advancements, and regional market shifts. Market Leadership in Transition The cancer nanomedicine space is evolving rapidly, with companies investing in product differentiation and late-stage R&D. Liposomes remain the most commercially established carriers, while polymeric nanoparticles and dendrimers are seeing increased use due to their payload capacity and tumor selectivity (Chapter 6: Market Segment Analysis). Leading companies such as Pfizer, Novartis AG, and Jazz Pharmaceuticals are developing tailored nanocarrier systems for specific cancer indications, with a focus on breast and lung cancers. These therapies are being designed for better tumor penetration, reduced off-target toxicity and improved treatment outcomes (Chapter 7: Competitive Intelligence). Emerging Technologies and Investment Trends Innovation in nanomedicine is being fueled by multifunctional systems that integrate diagnosis, therapy, and monitoring. Technologies including quantum dots, cancer stem cell-targeting particles, and nanorobotics are moving closer to clinical translation, offering new capabilities in image-guided therapy and adaptive dosing. Strong capital inflow and increased partnerships between biotech firms and research institutions are accelerating development across early and mid-stage pipelines. These trends are unlocking commercialization potential, especially in minimally invasive therapies and immuno-nanomedicine (Chapter 5: Emerging Technologies and New Developments). Pipeline Assessment and Applications The oncology pipeline is steadily embracing nanotechnology as a cornerstone for targeted treatment development. Companies are advancing nanoparticle-based drug carriers with enhanced tumor penetration, improved bioavailability and reduced toxicity. These innovations are driving late-stage R&D across different types of cancers, such as breast and lung cancers, leukemia and melanoma. In parallel, there is growing interest in integrating diagnostic and therapeutic functions into single nanosystems. Platforms capable of simultaneous drug delivery and real-time tumor tracking are gaining momentum, offering the potential for adaptive dosing and early relapse detection (Chapter 6: Market Segment Analysis). Regulatory and Access Challenges Regulatory agencies, such as the U.S. FDA, European Medicines Agency (EMA), and other international bodies, are actively evolving frameworks to support the safe and effective approval of nanoscale cancer therapies. As manufacturers scale production, they must comply with stringent requirements related to materials handling, product traceability and lifecycle oversight (Chapter 4: Regulatory Landscape). Challenges such as development costs, access limitations in low-income regions, and a shortage of oncology specialists trained in nanomedicine are slowing down broader adoption. Addressing these issues is essential to achieving long-term growth and equitable global impact (Chapter 3: Market Dynamics). Strategic Outlook: The Road Ahead With nanotechnology's role in oncology continuing to expand, companies are aligning R&D with long-term goals around innovation, clinical efficacy, and accessibility. Key companies are developing platforms that support patient-centered care, data-driven treatment personalization, and integration across diagnostic and therapeutic pathways (Chapter 2: Market Overview). As infrastructure improves and global interest in targeted therapies grows, nanomedicine is expected to become a cornerstone of modern cancer care. Firms prioritizing early diagnosis, adaptive delivery and long-term monitoring will be best positioned to lead the market forward (Chapter 7: Competitive Intelligence). Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $102.4 billion Market size forecast $265.4 billion Growth rate CAGR of 17.4% for the forecast period of 2024-2029 Segments covered Product type and cancer type Regions covered North America, Europe, Asia-Pacific, South America, Rest of the World Countries covered The U.S., Canada, Mexico, Germany, France, Italy, Spain, the U.K., Austria, Sweden, Denmark, Poland, Turkey, Switzerland, the Netherlands, China, Japan, India, South Korea, Australia, Thailand, Singapore, Malaysia, New Zealand, Vietnam, Brazil, Argentina, Colombia, Paraguay, Peru, Middle East and Africa Market drivers Increasing prevalence of cancer cases globally. Rise in government funding and pharmaceutical R&D spending. Nanoparticles in cancer treatment: Advantages. Precision targeting of cancer cells with nanomaterials. Additional Insights: Ultra-small and highly efficient: Nanoparticles are often smaller than a single cell; thus, it is easier for them to penetrate tumors and deliver drugs directly to cancer cells. Stealth functionality: These particles can be engineered to "cloak" themselves from the immune system, allowing them to circulate longer within the bloodstream. Multifunctional carriers: Nanoparticles can transport multiple drugs simultaneously, enabling combination therapies in a single delivery. Energy-interactive: They can absorb energy from external sources, supporting their role in advanced imaging or therapeutic enhancement. Next-level diagnostics: Nanoparticles can serve as highly sensitive imaging agents, enhancing early diagnosis and treatment precision. Leading companies include: AstraZeneca Baxter Boston Scientific Corp. Bristol-Myers Squibb Co. F. Hoffmann-La Roche Ltd. Jazz Pharmaceuticals Inc. Les Laboratoires Servier Novartis AG Pfizer Inc. Teva Pharmaceutical Industries Ltd. Navigate Uncertainty with ConfidenceIn times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we are here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape, providing you with the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That is why, for a limited time, we are offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights. Get your copy of the report directly from BCC Research. To request more information or complete your purchase, connect with us at info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. CONTACT: BCC Research Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301
Yahoo
an hour ago
- Yahoo
FDA Approved Anticancer Peptide Drug Conjugate Market Clinical Trials Insight
Global Peptide Drug Conjugate Market USD 1400 Million Opportunity Says Kuick Research In New Study Delhi, June 05, 2025 (GLOBE NEWSWIRE) -- Global Peptide Drug Conjugate Market, Drug Sales, Price, Dosage and Clinical Trials Insight 2030 Report Highlights: Global Peptide Drug Conjugate Market Opportunity: > USD 1400 Million Global Peptide Drug Conjugate Market Trends By Region and Indications Global Peptide Drug Conjugate Market Growth 2018-2024: > 300% Absolute Growth and 27% CAGR Growth Approved Peptide Drug Conjugate Dosage, Sales and Price Insight Approved Peptide Drug Conjugate Sales Global and Regional Insight: 2 Drugs Approved Global Peptide Drug Conjugate Clinical Trials Insight: > 30 Drugs Global Peptide Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase Peptide Drug Conjugate Proprietary Technologies and Methodologies Insight By Company Download Report: Peptide drug conjugates constitute a novel category of targeted therapies that make use of disease-targeting peptides to specifically deliver small molecule drugs to the target cells. This blended strategy enables drugs to be targeted more precisely to ailing tissues, minimizing systemic toxicity and maximizing therapeutic benefit. With more than 30 peptide drug conjugates candidates now in different stages of clinical trials, the domain is accelerating at breakneck speed. Most of these candidates are being developed and evaluated for oncology, where the demand for highly targeted therapies is still paramount. Nonetheless, investigations have also been pushed into neurodegenerative disease and inflammatory disorders, which suggests a wider therapeutic scope for this modality. As of May 2025, 2 peptide drug conjugates have been approved by the regulators. Novartis's Lutathera, a radiolabeled peptide for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), exemplifies the potential of targeted delivery in cancer. The second agent that has been approved, Pepaxti (melflufen), by Oncopeptides, is employed to treat multiple myeloma and demonstrates the utility of peptide to enhance the therapeutic index of known cytotoxic agents. All these achievements underscore the potential for peptide drug conjugates and have opened up doors for more firms to enter the pipeline for developing new candidates. Platform technologies are leading the way in driving peptide drug conjugate innovation. For example, PeptiDream's PDPS (Peptide Discovery Platform System) leverages massive libraries of macrocyclic peptides to quickly find high-affinity binders. They are optimized as targeting agents in peptide drug conjugates, enabling more targeted drug delivery. By targeting cytotoxic payloads directly to disease-associated receptors, these technologies reduce off-target effects, improving efficacy and safety for patients. The growing use of such platforms by biotech companies and pharmaceutical companies highlights their significance in the present drug development scenario. Regulatory assistance is also supporting the development of peptide drug conjugates. Sudocetaxel zendusortide (TH1902), a peptide drug conjugate from Theratechnologies, was granted the Fast Track Designation by the FDA. This candidate has been designed against sortilin-expressing solid tumors and is undergoing Phase 1 clinical trials. As the first compound from Theratechnologies' SORT1+ Technology™, it is an example of innovation in peptide targeting and an accelerated regulatory pathway that allows for accelerated development. Designations such as these not only support the therapeutic potential of these compounds but also foster investment and accelerate clinical advancement. The peptide drug conjugate field involves a diverse range of stakeholders, including major pharmaceutical companies like Novartis and Oncopeptides, as well as specialized biotechnology firms such as Bicycle Therapeutics and Theratechnologies. Additionally, contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) are increasingly becoming integral to the development process, providing essential services from early-stage discovery through to clinical and commercial manufacturing. In spite of this momentum, market hurdles exist. One major hindrance is the complexity of peptide drug conjugate manufacturing, which sometimes necessitates specialized facilities and intense quality control, potentially pushing up development expense. To overcome it, strategic alliances with seasoned CDMOs can streamline manufacturing and lower operational costs. Regulatory complexity regarding newer payloads or novel peptide-linker chemistries is another hurdle. Anticipation of the regulatory agencies through proactive interaction and utilization of existing designations can smooth over the complexity. Looking to the future, the prospects for peptide-drug conjugates are encouraging. As ever improving technology platforms advance and additional clinical information becomes available, peptide drug conjugates are destined to become a staple of targeted therapy, not just oncology, but perhaps a wide variety of chronic and orphan diseases. CONTACT: Neeraj Chawla Research Head Kuick Research neeraj@ +91-470679900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
